Medicare Enrolled

Dr. Ernest Cochran, M.D.

Medical Oncology · Paris, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
3550 NE LOOP 286, Paris, TX 75460
9037850031
In practice since 2006 (19 years)
NPI: 1710920269 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Cochran from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Cochran? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Cochran

Dr. Ernest Cochran is a medical oncology in Paris, TX, with 19 years in practice. Based on federal Medicare data, Dr. Cochran performed 63,607 Medicare services across 2,584 unique beneficiaries.

Between the years covered by Open Payments, Dr. Cochran received a total of $882 from 11 pharmaceutical and/or device companies across 14 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Cochran is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 16% volume in TX$ $882 industry payments

Medicare Practice Summary

Medicare Utilization ↗
63,607
Medicare services
Top 16% in TX for medical oncology
2,584
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,348 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Iron infusion (Feraheme)25,500$0$5
Pembrolizumab injection (Keytruda)9,600$43$135
Anti-nausea injection (fosaprepitant)8,400$0$5
Darbepoetin injection (Aranesp) for anemia6,915$2$20
Denosumab injection (Prolia/Xgeva)1,920$18$64
Contrast dye for imaging (iodine-based)1,909$0$3
Dexamethasone injection (steroid)1,813$0$1
Immune globulin infusion (Octagam)1,450$33$233
Anti-nausea injection (Aloxi/palonosetron)760$1$114
Injection, granisetron hydrochloride, 100 mcg580$0$24
Blood draw (venipuncture)512$8$20
Complete blood count (CBC) with differential506$8$36
Office visit, established patient (20-29 min)449$57$250
Comprehensive metabolic blood panel304$10$64
Lactate dehydrogenase (enzyme) level283$6$31
Injection of additional new drug or substance into vein268$12$108
Administration of chemotherapy into vein, 1 hour or less236$96$707
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less212$22$157
Drug injection, under skin or into muscle199$10$96
Injection, carboplatin, 50 mg195$2$300
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less114$48$313
Ferritin level test (iron stores)105$13$60
Iron level test102$6$27
Iron binding capacity test102$9$35
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle83$54$211
Injection, diphenhydramine hcl, up to 50 mg81$1$7
Office visit, established patient (30-39 min)68$84$368
Injection, zoledronic acid, 1 mg68$7$431
Administration of additional new drug or substance into vein, 1 hour or less66$49$344
Leuprolide acetate (for depot suspension), 7.5 mg57$139$3,675
Administration of chemotherapy into vein, each additional hour56$21$161
New patient office visit (45-59 min)53$113$565
Microscopic examination for white blood cells with manual cell count51$4$22
Complete blood count (CBC), automated51$6$34
Basic metabolic blood panel48$8$49
Office visit, established patient (10-19 min)48$35$150
Infusion, normal saline solution , 1000 cc48$2$19
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour47$16$100
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle44$22$145
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries37$90$657
Nuclear medicine study from skull base to mid-thigh with ct scan36$1,109$4,802
Reticulated (young) platelet measurement36$35$143
Infusion into a vein for hydration, each additional hour29$10$75
Irrigation of implanted venous access drug delivery device28$16$114
Administration of additional new drug or substance into vein using push technique26$42$289
Unclassified drugs26$1$8
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion22$14$94
Red blood count, automated test21$4$23
Ct scan of chest with contrast18$39$821
CT scan of abdomen and pelvis with contrast13$163$1,067
CT scan of chest, without contrast12$43$686
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
43.1% high complexity
52.2% medium
4.7% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$882
Total received (2019-2024)
Avg $147/year across 6 years
Bottom 28% in TX for medical oncology
11
Companies
14
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$743 (84.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$139 (15.8%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$103
2023
$37
2022
$25
2021
$293
2020
$165
2019
$259

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Myriad Genetic Laboratories, Inc.
$257
Astellas Pharma US Inc
$125
Rigel Pharmaceuticals, Inc.
$125
Ethicon US, LLC
$122
ABBVIE INC.
$103
E.R. Squibb & Sons, L.L.C.
$40
Pharmacyclics LLC, An AbbVie Company
$37
Pharmacyclics LLC, an AbbVie Company
$25
Myovant Sciences Inc.
$24
Janssen Biotech, Inc.
$12
Gilead Sciences, Inc.
$12
Top 3 companies account for 57.5% of total payments
Associated products mentioned in payments ›
EPKINLY · Erleada · IMBRUVICA · NEUWAVE Flex Microwave Ablation System · OPDIVO · ORGOVYX · Tavalisse · XOSPATA · myChoice CDx
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (84%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $1 per 100 Medicare services performed
Looking for a medical oncology in Paris?
Compare medical oncologys in the Paris area by procedure volume, costs, and industry payment transparency.
Browse medical oncologys nearby

Geographic Context

Medical Oncologys within 10 mi
3
Per 100K population
5.9
County median income
$61,122
Nearest hospital
PARIS REGIONAL MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Cochran is a mixed practice specialist, with above-average Medicare volume (top 16% in TX), and low-engagement industry engagement, with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Cochran experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Cochran performed 25,500 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Cochran receive payments from pharmaceutical companies?
Yes. Dr. Cochran received a total of $882 from 11 companies across 14 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Cochran's costs compare to other medical oncologys in Paris?
Dr. Cochran's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Cochran) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →